Skip to content

Study · Not a test of the peptide alone · 2026

2 results

Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.

Matsunuma S, Hirota Y, Yoshimoto K

International journal of clinical pharmacology and therapeutics1 May 2026

PMID41582648 (opens in a new tab)DOI10.5414/cp204899 (opens in a new tab)PepBankPUB-41582648
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes taking oral semaglutide, the HbA1c reduction at 52 weeks was greater with PPI co-administration (-1.56%) than without (-1.08%).

    In plain wordsIn people with type 2 diabetes on oral semaglutide, HbA1c fell more with a PPI than without one.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at 52 weeks
    Study

    n = 66

    Comparator
    Oral semaglutide without PPI
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −1.56%
    oral semaglutide with PPI
    HbA1c change
    −1.08%
    oral semaglutide without PPI

    Source sentences

    Summary
    HbA1c reduction at 52 weeks was significantly greater in the w/PPI group (-1.56 ± 0.37%) than in the w/o PPI group (-1.08 ± 0.76%, p = 0.024).
    1 context sentence
    Summary · context
    This single-center retrospective study included patients with type 2 diabetes who received oral semaglutide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In adults with type 2 diabetes taking oral semaglutide, adverse event incidence did not differ significantly between those with PPI (24.0%) and without PPI (31.7%).

    In plain wordsIn people on oral semaglutide, side effects were not clearly different between those who took a PPI and those who did not.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse event incidence
    Study

    n = 66

    Comparator
    Oral semaglutide without PPI
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body

    Measurements

    Adverse event incidence
    24%
    with PPI
    Adverse event incidence
    31.7%
    without PPI

    Source sentences

    Summary
    The incidences of adverse events were 24.0% and 31.7% in the w/PPI and w/o PPI groups, respectively (p = 0.502).
    1 context sentence
    Summary · context
    This single-center retrospective study included patients with type 2 diabetes who received oral semaglutide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.